Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.
Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.
A group of 445 postmenopausal women with symptomatic vaginal atrophy (VA) were randomly assigned to receive lasofoxifene (0.25 mg/day or 0.5 mg/day) or placebo. Clinical effect was assessed using vaginal pH and vaginal cytology to determine the maturation index (superficial, intermediate, and parabasal cells). At screening, women were required to have no more than 5% superficial cells and vaginal pH of more than 5.
The results were clear, Dr. Gass said. By week 12, there were adjusted mean decreases in parabasal cells of 38% for the lasofoxifene 0.25 group, 37% for the lasofoxifene 0.5 group, and 3% for the placebo group (P
Gass M, Kagan R, Simon J, Spino C, Barcomb L. Objective measures of vaginal atrophy are improved with lasofoxifene, a next-generation selective estrogen receptor modulator. Obstet Gynecol. 2005;105(4 suppl):71S.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More